BiotechTube

ASP8082 + morphine + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Use Disorder

Conditions

Opioid Use Disorder

Trial Timeline

Jun 30, 2020 → Sep 11, 2020

NCT ID
NCT04448561

About ASP8082 + morphine + Placebo

ASP8082 + morphine + Placebo is a phase 1 stage product being developed by Astellas Pharma for Opioid Use Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04448561. Target conditions include Opioid Use Disorder.

What happened to similar drugs?

8 of 20 similar drugs in Opioid Use Disorder were approved

Approved (8) Terminated (6) Active (7)
✅Naldemedine + PlaceboShionogiApproved
✅Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
✅Naltrexone for extended-release injectable suspension + Oral naltrexoneAlkermesApproved
✅NaltrexoneAlkermesApproved
✅VIVITROL 380mgAlkermesApproved
✅methylnaltrexone + placeboBausch HealthApproved
✅Methylnaltrexone bromideBausch HealthApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04448561Phase 1Completed

Competing Products

20 competing products in Opioid Use Disorder

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
29
SUBLOCADEIndivior PLCPhase 3
29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
27
Naldemedine + PlaceboShionogiPhase 3
40
Naldemedine + PlaceboShionogiApproved
50
NaldemedineShionogiPhase 1/2
39
Naldemedine + PlaceboShionogiPhase 3
40
Placebo + NaldemedineShionogiPhase 2
35
Naldemedine + PlaceboShionogiPhase 3
40
Naldemedine + PlaceboShionogiPhase 2
35
NaloxegolKyowa KirinPre-clinical
26
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
18
NaloxegolKyowa KirinPre-clinical
26
NaloxegolKyowa KirinPre-clinical
26
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
42
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
32
Naloxegol + NaloxegolAstraZenecaPhase 1
29
NKTR-118 + Usual careAstraZenecaPhase 3
40
Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
43